Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 16, 2009

Clemson University Obtains $9.3M for Tissue Regeneration Center

  • Clemson University received a $9.3 million, five-year NIH grant to establish a Center of Biomedical Research Excellence (COBRE) for Tissue Regeneration. Faculty from the Medical University of South Carolina and the University of South Carolina will also collaborate, providing expertise in medicine and developmental biology.

    “This new Clemson COBRE will significantly improve our collaborative efforts in South Carolina to recruit, train, and retain researchers with cross-disciplinary skills in the area of regenerative medicine,” according to Clemson University president, James F. Barker.

    Additionally, points out Naren Vyavahare, Hunter Endowed chair and professor of bioengineering, “the center's research focus will be on tissue regeneration through cell biomaterials’ interactions with the goal of restoring functional tissues.” Vyavahare will also act as principal investigator and the center's director.

    COBRE is funded by the NIH National Center for Research Resources Institutional Development Award program. The effort aims to increase the number of NIH-funded biomedical researchers in the nation and to strengthen the biomedical research capacity of individual universities. The goal is to create worldclass core facilities and to provide funding and mentoring for early career investigators.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »